WO2006029262A3 - Conditioned medium of autologous or allogenic progenitor cells for angiogenesis treatment - Google Patents

Conditioned medium of autologous or allogenic progenitor cells for angiogenesis treatment Download PDF

Info

Publication number
WO2006029262A3
WO2006029262A3 PCT/US2005/031982 US2005031982W WO2006029262A3 WO 2006029262 A3 WO2006029262 A3 WO 2006029262A3 US 2005031982 W US2005031982 W US 2005031982W WO 2006029262 A3 WO2006029262 A3 WO 2006029262A3
Authority
WO
WIPO (PCT)
Prior art keywords
conditioned medium
angiogenesis
cell
autologous
progenitor cells
Prior art date
Application number
PCT/US2005/031982
Other languages
French (fr)
Other versions
WO2006029262A2 (en
Inventor
Ran Kornowski
Shmuel Fuchs
Stephen E Epstein
Martin B Leon
Original Assignee
Myocardial Therapeutics Inc
Ran Kornowski
Shmuel Fuchs
Stephen E Epstein
Martin B Leon
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Myocardial Therapeutics Inc, Ran Kornowski, Shmuel Fuchs, Stephen E Epstein, Martin B Leon filed Critical Myocardial Therapeutics Inc
Priority to JP2007531326A priority Critical patent/JP2008512198A/en
Priority to EP05796100A priority patent/EP1789538A2/en
Priority to AU2005282384A priority patent/AU2005282384B2/en
Priority to CA002578815A priority patent/CA2578815A1/en
Publication of WO2006029262A2 publication Critical patent/WO2006029262A2/en
Publication of WO2006029262A3 publication Critical patent/WO2006029262A3/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/0018—Culture media for cell or tissue culture
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/28—Bone marrow; Haematopoietic stem cells; Mesenchymal stem cells of any origin, e.g. adipose-derived stem cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/195—Chemokines, e.g. RANTES
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0652—Cells of skeletal and connective tissues; Mesenchyme
    • C12N5/0662—Stem cells
    • C12N5/0663—Bone marrow mesenchymal stem cells (BM-MSC)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/10—Growth factors
    • C12N2501/115—Basic fibroblast growth factor (bFGF, FGF-2)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/21—Chemokines, e.g. MIP-1, MIP-2, RANTES, MCP, PF-4
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/22—Colony stimulating factors (G-CSF, GM-CSF)

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biotechnology (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Genetics & Genomics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Wood Science & Technology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Cell Biology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Hematology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Rheumatology (AREA)
  • Virology (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Materials For Medical Uses (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

A therapeutic composition is provided that comprises a cell-free conditioned medium containing mixed secretion products of isolated angiogenic progenitor cells obtained from bone marrow, peripheral blood, or adipose tissue. The composition may additionally contain angiogenesis-promoting proteins obtained by transfecting the progenitors cells in culture with an angiogenesis promoting transgene. The composition is useful to promote angiogenesis when introduced into or adjacent to an ischemic site in a patient, such as in myocardium or peripheral limb. Methods are also provided for utilizing such cell-free conditioned medium to deliver angiogenesis-promoting proteins to a patient. The cell-free conditioned medium can also be injected into the blood stream for delivery to the ischemic tissue. The cells can derive from either an autologous or allogenic source and can be lyophilized or frozen for storage.
PCT/US2005/031982 2004-09-08 2005-09-07 Conditioned medium of autologous or allogenic progenitor cells for angiogenesis treatment WO2006029262A2 (en)

Priority Applications (4)

Application Number Priority Date Filing Date Title
JP2007531326A JP2008512198A (en) 2004-09-08 2005-09-07 Conditioned medium of autologous or allogeneic progenitor cells for the treatment of angiogenesis
EP05796100A EP1789538A2 (en) 2004-09-08 2005-09-07 Conditioned medium of autologous or allogenic progenitor cells for angiogenesis treatment
AU2005282384A AU2005282384B2 (en) 2004-09-08 2005-09-07 Conditioned medium of autologous or allogenic progenitor cells for angiogenesis treatment
CA002578815A CA2578815A1 (en) 2004-09-08 2005-09-07 Conditioned medium of autologous or allogenic progenitor cells for angiogenesis treatment

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US60827204P 2004-09-08 2004-09-08
US60/608,272 2004-09-08

Publications (2)

Publication Number Publication Date
WO2006029262A2 WO2006029262A2 (en) 2006-03-16
WO2006029262A3 true WO2006029262A3 (en) 2009-04-09

Family

ID=36036998

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2005/031982 WO2006029262A2 (en) 2004-09-08 2005-09-07 Conditioned medium of autologous or allogenic progenitor cells for angiogenesis treatment

Country Status (6)

Country Link
EP (1) EP1789538A2 (en)
JP (1) JP2008512198A (en)
CN (1) CN101432420A (en)
AU (1) AU2005282384B2 (en)
CA (1) CA2578815A1 (en)
WO (1) WO2006029262A2 (en)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FI20085839A0 (en) * 2008-09-08 2008-09-08 Timo Ylikomi Methods and tools for soft tissue technology
US8911963B2 (en) 2010-04-05 2014-12-16 Medstar Health Research Institute, Inc. Conditioned medium obtained from stem cells and its use in therapy
US11684574B2 (en) 2016-06-30 2023-06-27 University of Pittsburgh—of the Commonwealth System of Higher Education Artificial cells and delivery devices for use in tissue engineering, and related methods

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040131601A1 (en) * 2000-03-30 2004-07-08 Foundry Networks, Inc., A Delaward Corporation Injection of bone marrow-derived cells and medium for angiogenesis
US6372494B1 (en) * 1999-05-14 2002-04-16 Advanced Tissue Sciences, Inc. Methods of making conditioned cell culture medium compositions

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
REHMAN, J ET AL.: "Peripheral Blood ''Endothelial Progenitor Cells'' Are Derived From Monocyte/Macrophages and Secrete Angiogenic Growth Factors.", CIRCULATION, vol. 107, 2003, pages 1164 - 1169, XP008022340 *
WANG, C. ET AL.: "Mechnical, Cellular, and Molecular Factors Interact to Modulate Circulating Endothelial Cell Progenitors.", AMERICAN JOURNAL OF PHYSIOLOGICAL HEART CIRCULATION PHYSIOLOGY, vol. 286, 2004, pages H1985 - H1993, XP008117720 *

Also Published As

Publication number Publication date
AU2005282384B2 (en) 2011-09-01
JP2008512198A (en) 2008-04-24
EP1789538A2 (en) 2007-05-30
WO2006029262A2 (en) 2006-03-16
CA2578815A1 (en) 2006-03-16
AU2005282384A1 (en) 2006-03-16
CN101432420A (en) 2009-05-13

Similar Documents

Publication Publication Date Title
Liu et al. Current methods for skeletal muscle tissue repair and regeneration
De Girolamo et al. Regenerative approaches for the treatment of early OA
Lee et al. Cartilage repair by mesenchymal stem cells: clinical trial update and perspectives
Guerado et al. Challenges of bone tissue engineering in orthopaedic patients
Salibian et al. Stem cells in plastic surgery: a review of current clinical and translational applications
Ortved Regenerative medicine and rehabilitation for tendinous and ligamentous injuries in sport horses
Tabata Significance of release technology in tissue engineering
Sclafani Applications of platelet-rich fibrin matrix in facial plastic surgery
Mojallal et al. Influence of negative pressure when harvesting adipose tissue on cell yield of the stromal–vascular fraction
Pountos et al. Biology of mesenchymal stem cells
Schmitt et al. Application of stem cells in orthopedics
Ahmed et al. Fibrin glues in combination with mesenchymal stem cells to develop a tissue-engineered cartilage substitute
De Ugarte et al. Future of fat as raw material for tissue regeneration
Andia et al. New biotechnologies for musculoskeletal injuries
Liou et al. Effect of platelet-rich plasma on chondrogenic differentiation of adipose-and bone marrow-derived mesenchymal stem cells
Coelho et al. Intraoperative stem cell therapy
Andia et al. Current concepts and translational uses of platelet rich plasma biotechnology
Pountos et al. Growing bone and cartilage: the role of mesenchymal stem cells
Giannoudis et al. Bone regeneration strategies: current trends but what the future holds?
US20110052533A1 (en) Compositions and Methods for Cartilage Repair
Shenaq et al. Mesenchymal progenitor cells and their orthopedic applications: forging a path towards clinical trials
Jeschke et al. Wound coverage technologies in burn care: novel techniques
WO2005007811A3 (en) Injection of bone marrow-derived cells and medium for angiogenesis
Uzieliene et al. Non-viral gene therapy for osteoarthritis
Wang et al. Potential of cardiac stem/progenitor cells and induced pluripotent stem cells for cardiac repair in ischaemic heart disease

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KM KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NG NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SM SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): BW GH GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LT LU LV MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 2005282384

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 2578815

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 2007531326

Country of ref document: JP

NENP Non-entry into the national phase

Ref country code: DE

ENP Entry into the national phase

Ref document number: 2005282384

Country of ref document: AU

Date of ref document: 20050907

Kind code of ref document: A

WWP Wipo information: published in national office

Ref document number: 2005282384

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 2250/DELNP/2007

Country of ref document: IN

WWE Wipo information: entry into national phase

Ref document number: 200580033301.3

Country of ref document: CN

WWE Wipo information: entry into national phase

Ref document number: 2005796100

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 2005796100

Country of ref document: EP